3-isobutyl 5-methyl 1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)-3,5-pyridinedicarboxylate | 104196-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-isobutyl 5-methyl 1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)-3,5-pyridinedicarboxylate
• 英文别名: 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-pyridin-4-yl-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 104196-49-8
• 化学式: C₁₉H₂₄N₂O₄
• 分子量: 344.411
• InChiKey: FOBXOCHDKZYPND-UHFFFAOYSA-N

物化性质

• 沸点：
  467.6±45.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  叔-丁基氯甲酸酯 、 3-isobutyl 5-methyl 1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)-3,5-pyridinedicarboxylate 在 sodium tetrahydroborate 作用下， 生成 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-[1-[(2-methylpropan-2-yl)oxycarbonyl]-2H-pyridin-4-yl]-1,4-dihydropyridine-3,5-dicarboxylate
  参考文献：
  名称：

  Synthesis and calcium channel antagonist activity of dialkyl 4-(dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylates

  摘要：

  The sodium borohydride reduction of 3,5-disubstituted 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)pyridines 2 and 5 in the presence of methyl, phenyl, or tert-butyl chloroformate afforded the respective 4-(dihydropyridinyl)-1,4-dihydropyridines 4 and 6 in good yield. Products 4 comprised a mixture of the 1,2- and 1,6-dihydropyridinyl regioisomers 4a and 4b where 4a was always the predominant regioisomer. Compounds possessing a 4-[dihydro-1-(phenoxycarbonyl)-3-pyridinyl] substituent, such as 26, were also a mixture of two regioisomers 26a and 26b, and each regioisomer existed as a mixture of two rotamers in Me2SO-d6 at 25 degrees C (26a', 26a'', and 26b', 26b'') due to restricted rotation about the nitrogen-to-carbonyl carbamate bond. The calcium antagonist activities for 4 and 6 were determined by using the muscarinic receptor-mediated Ca2+-dependent contraction of guinea pig ileal longitudinal smooth muscle. The relative order of activities for the 4-(dihydropyridinyl) analogues was 4-(dihydro-3-pyridinyl) greater than 4-(dihydro-4-pyridinyl). Increasing the size of the C-3(5) alkyl ester substituents increased activity. Compounds having nonidentical ester substituents were more active than those having identical ester substituents. Replacement of the C-3 and/or C-5 ester substituents by a cyano substituent(s) decreased activity significantly. An approximate 1:1 correlation between the IC50 value for inhibition of [3H]nitrendipine binding and inhibition of the tonic component of the muscarinic-induced contractile response was observed. The test results suggest that a 4-(dihydropyridinyl) substituent is bioisosteric with a 4-(nitrophenyl) substituent on a 1,4-dihydropyridine ring where m- and p-nitrophenyl are bioisosteric with the 4-[1,2(1,6)-dihydro-3-pyridinyl] 4 and 4-(1,2-dihydro-4-pyridinyl) 6 isomers, respectively.

  DOI：

  10.1021/jm00387a010
• 作为产物：
  描述：

  4-吡啶甲醛 、 乙酰乙酸异丁酯 、 3-氨基巴豆酸甲酯 以 乙醇 为溶剂， 反应 16.0h， 以76%的产率得到3-isobutyl 5-methyl 1,4-dihydro-2,6-dimethyl-4-(4-pyridyl)-3,5-pyridinedicarboxylate
  参考文献：
  名称：

  1,4-二氢-2,6-二甲基-4-（吡啶基）-3,5-吡啶二羧酸二烷基酯的合成及钙通道拮抗剂活性。

  摘要：

  乙酰乙酸烷基酯3与3-氨基巴豆酸甲酯（4）和吡啶甲醛5的汉茨缩合反应得到不对称的1,4-二氢-2,6-二甲基-4-（吡啶基）-3,5-吡啶二甲酸烷基甲基酯6，而缩合反应3与5和氢氧化铵反应得到对称的1,4-二氢-2,6-二甲基-4-（吡啶基）-3,5-吡啶二羧酸二烷基酯7。二取代的1,4-二氢-3的钙通道拮抗剂活性使用豚鼠回肠纵向平滑肌的毒蕈碱受体介导的Ca2 +依赖性收缩测定1,5-吡啶二甲酸6,7和9。异构吡啶基类似物6和7的相对效价顺序是2-吡啶基大于3-吡啶基大于4-吡啶基。增加烷基酯取代基的大小可增强活性。具有相同酯取代基的化合物比具有相同酯取代基的化合物更有效。用氰基取代基代替C-3和/或C-5酯取代基明显降低了活性。观察到抑制[3H]硝苯地平结合的IC50值与抑制毒蕈碱诱导的收缩反应的补品成分之间的近似1：1关系。测试结果表明4-（吡啶基）取代基在1,4-二氢吡啶环系统上具有

  DOI：

  10.1021/jm00162a016

文献信息

• Synthesis and Calcium Channel Antagonist Activity of Dialkyl 1,4-Dihydro-2,6-dimethyl-4-[4-(1-methoxycarbonyl-1,4-dihydropyridyl)]-3,5- pyridinedicarboxylates
  作者：Manian Ramesh、Wandikayi C. Matowe、Michael W. Wolowyk、Edward E. Knaus

  DOI：10.1002/(sici)1521-4184(199911)332:11<385::aid-ardp385>3.0.co;2-9

  日期：1999.11

  A novel class of dialkyl 1,4‐dihydro‐2,6‐dimethyl‐4‐[4‐(1‐methoxycarbonyl‐ 1,4‐dihydropyridyl)]‐3,5‐pyridinedicarboxylates (8—14) were synthesized and evaluated as calcium channel antagonists. The differences in activity among members of this new class of compounds was less than one log unit (IC50 range of 1.12 × 10‐6 to 8.57 × 10‐6 M), relative to the reference drug nifedipine (IC50 = 1.43 × 10‐8

  合成了一类新的 1,4-二氢-2,6-二甲基-4-[4-(1-甲氧羰基-1,4-二氢吡啶基)]-3,5-吡啶二羧酸二烷基酯 (8-14) 并评估为钙通道拮抗剂。相对于参考药物硝苯地平（IC50 = 1.43 × 10-8），这类新化合物成员之间的活性差异小于一个 log 单位（IC50 范围为 1.12 × 10-6 至 8.57 × 10-6 M）米）。无论二烷基（Me、Et、i-Pr、i-Bu）酯取代基的大小如何，效力的微小差异归因于 N-CO2Me 取代基与 C-3 和C-5 酯取代基进行非键合空间相互作用。这类新化合物中的 4- [4- (1-甲氧羰基 - 1,4- 二氢吡啶基) 部分是生物等排的，具有 C- 4 4-硝基苯基或 4- 吡啶基，在经典 1 中被取代，
• DAGNINO L.; LI-KWONG-KEN MOY CH.; WYNN HLA; WOLOWYK M. W.; TRIGGLE CH. R.+, J. MED. CHEM., 30,(1987) N 4, 640-646
  作者：DAGNINO L.、 LI-KWONG-KEN MOY CH.、 WYNN HLA、 WOLOWYK M. W.、 TRIGGLE CH. R.+

  DOI：——

  日期：——